Edition:
United Kingdom

Atara Biotherapeutics Inc (ATRA.OQ)

ATRA.OQ on NASDAQ Stock Exchange Global Select Market

23.21USD
24 May 2019
Change (% chg)

$-0.28 (-1.19%)
Prev Close
$23.49
Open
$23.66
Day's High
$24.32
Day's Low
$22.77
Volume
120,012
Avg. Vol
146,211
52-wk High
$52.65
52-wk Low
$22.36

Latest Key Developments (Source: Significant Developments)

Atara Biotherapeutics Reports Q1 Loss Per Share Of $1.44
Thursday, 9 May 2019 

May 9 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS AND RECENT OPERATIONAL PROGRESS.Q1 LOSS PER SHARE $1.44.Q1 EARNINGS PER SHARE ESTIMATE $-1.51 -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS AS OF MARCH 31, 2019 TOTALED $237.5 MILLION.ATARA BIOTHERAPEUTICS - BELIEVES CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS AS OF MARCH 31 WILL BE SUFFICIENT TO FUND PLANNED OPERATIONS TO MID-2020.  Full Article

Atara Biotherapeutics CEO To Step Down; Board Initiates Search For Successor
Thursday, 3 Jan 2019 

Jan 3 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES PLANNED CHIEF EXECUTIVE OFFICER TRANSITION.ATARA BIOTHERAPEUTICS INC - CIECHANOVER WILL REMAIN IN HIS ROLE AS PRESIDENT AND CEO UNTIL EARLIER OF APPOINTMENT OF HIS SUCCESSOR OR JUNE 30, 2019.ATARA BIOTHERAPEUTICS INC - ISAAC CIECHANOVER PLANS TO STEP DOWN AS COMPANY'S PRESIDENT AND CHIEF EXECUTIVE OFFICER.ATARA BIOTHERAPEUTICS INC - BOARD OF DIRECTORS HAS INITIATED A SEARCH FOR ISAAC CIECHANOVER'S SUCCESSOR.  Full Article

Atara Biotherapeutics Reports Q3 Loss Per Share Of $1.29
Tuesday, 6 Nov 2018 

Nov 6 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS AND RECENT OPERATIONAL PROGRESS.Q3 LOSS PER SHARE $1.29.Q3 EARNINGS PER SHARE VIEW $-1.13 -- THOMSON REUTERS I/B/E/S.ATARA BIOTHERAPEUTICS- CASH, CASH EQUIVALENTS & SHORT-TERM INVESTMENTS AS OF SEPT 30 WAS $364.5 MILLION, SUFFIECIENT TO FUND PLANNED OPERATION TO MID-2020.ATARA BIOTHERAPEUTICS - INITIAL RESULTS FROM OFF-THE-SHELF, ALLOGENEIC ATA188 MULTIPLE SCLEROSIS PROGRAM ARE ANTICIPATED IN FIRST HALF OF 2019.  Full Article

Atara Biotherapeutics prices public offering of stock at $35 per share​
Thursday, 1 Mar 2018 

Feb 28 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.ATARA BIOTHERAPEUTICS - ‍PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 4.3 MILLION SHARES OF ITS COMMON STOCK AT A PRICE TO PUBLIC OF $35.00 PER SHARE​.  Full Article

Atara Says Commenced Underwritten Public Offering Of $150 Mln Shares Of Common Stock
Tuesday, 27 Feb 2018 

Feb 27 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK.ATARA BIOTHERAPEUTICS - COMMENCED UNDERWRITTEN PUBLIC OFFERING OF $150 MILLION OF ITS SHARES OF COMMON STOCK.  Full Article

Atara Biotherapeutics Posts Q4 Loss Of $1.15 Per Share
Tuesday, 27 Feb 2018 

Feb 27 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND RECENT OPERATIONAL PROGRESS.QTRLY LOSS PER SHARE $1.15.CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS AS OF DECEMBER 31, 2017 TOTALED $166.1 MILLION.Q4 EARNINGS PER SHARE VIEW $-1.14 -- THOMSON REUTERS I/B/E/S.  Full Article

Atara Biotherapeutics Says CFO Intends To Retire In April 2018
Wednesday, 21 Feb 2018 

Feb 21 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES CHIEF FINANCIAL OFFICER INTENTION TO RETIRE IN APRIL 2018.ATARA BIOTHERAPEUTICS INC - ‍JOHN MCGRATH, EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER, INTENDS TO RETIRE FROM CO AS OF APRIL 27, 2018​.  Full Article

Atara Biotherapeutics Gets FDA Clearance To Proceed With Multiple Sclerosis study
Wednesday, 10 Jan 2018 

Jan 10 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES FDA CLEARANCE TO PROCEED WITH ENROLLMENT AT U.S. SITES FOR ONGOING GLOBAL PHASE 1 CLINICAL STUDY TO EVALUATE ATA188 IN PATIENTS WITH PROGRESSIVE OR RELAPSING-REMITTING MULTIPLE SCLEROSIS.ATARA BIOTHERAPEUTICS INC - FIRST RESULTS FROM ATA188 PHASE 1 STUDY IN PATIENTS WITH PROGRESSIVE MS IN FIRST HALF OF 2019.  Full Article

Camber Capital Management Reports 6.7 Pct Passive Stake In Atara Biotherapeutics
Friday, 5 Jan 2018 

Jan 5 (Reuters) - CAMBER CAPITAL MANAGEMENT LLC ::CAMBER CAPITAL MANAGEMENT LLC REPORTS A 6.7 PERCENT PASSIVE STAKE IN ATARA BIOTHERAPEUTICS AS OF JANUARY 04 - SEC FILING.  Full Article

Atara Biotherapeutics prices public offering of 7 mln shares at $18.25 per share
Thursday, 4 Jan 2018 

Jan 3 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 7.00 MILLION COMMON SHARES PRICED AT $18.25PER SHARE.  Full Article